2024-07-03 09:54:32 ET
Summary
- Adaptimmune Therapeutics is focused on late-stage development of cell therapy for cancer, particularly in sarcoma management.
- Pipeline updates include progress on afami-cel for soft tissue sarcomas and lete-cel for synovial sarcoma.
- Financially, ADAP has a cash runway of around 3 quarters, with potential resources from collaborations and agreements extending it further.
Topline Summary and Update
Read the full article on Seeking Alpha
For further details see:
Adaptimmune: How The Story Is Shaping Up For The Latter Half Of 2024